LEXX vs AIXI Comparison

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

XIAO-I Corp operates as a cognitive artificial intelligence company. Using its proprietary intellectual property technologies, the company has developed and commercialized various core technologies, such as Conversational AI, Knowledge Fusion, Intelligence Voice, Hyperautomation, Data Intelligence, Cloud, Intelligent Construction Support, Vision Analysis, Intelligent Hardware Support, and Metaverse. Additionally, it has developed Hua Zang Universal Large Language Model. XIAO-I offers two different product lines: Model as a service (MaaS) and non-MaaS. Key revenue is derived from the non-MaaS product line, which comprises needs assessment, solution design and architecture planning, development and configuration, deployment, and implementation of non-model (mainly cloud platform) products.